IL321711A - Composition, immune cells comprising same, and use of said immune cells - Google Patents

Composition, immune cells comprising same, and use of said immune cells

Info

Publication number: IL321711A
Authority: IL; Israel
Prior art keywords: sequence; molecule; transposase; protein; complementary
Prior art date: 2022-12-28

Application number

IL321711A

Other languages

English (en)

Hebrew (he)

Original Assignee

Quidditas Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2022-12-28

Filing date

2023-12-28

Publication date

2025-08-01

2023-12-28 Application filed by Quidditas Sa filed Critical Quidditas Sa

2025-08-01 Publication of IL321711A publication Critical patent/IL321711A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Crystallography & Structural Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IL321711A 2022-12-28 2023-12-28 Composition, immune cells comprising same, and use of said immune cells IL321711A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
BE20226101A BE1031219B1 (fr)	2022-12-28	2022-12-28	Composition, cellules immunitaires la comprenant et utilisation de ces dernières
PCT/EP2023/087873 WO2024141570A1 (fr)	2022-12-28	2023-12-28	Composition, cellules immunitaires la comprenant et utilisation de ces dernières

Publications (1)

Publication Number	Publication Date
IL321711A true IL321711A (en)	2025-08-01

Family

ID=85157004

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL321711A IL321711A (en)	2022-12-28	2023-12-28	Composition, immune cells comprising same, and use of said immune cells

Country Status (8)

Country	Link
EP (1)	EP4623080A1 (fr)
JP (1)	JP2026501380A (fr)
KR (1)	KR20250127145A (fr)
CN (1)	CN120569472A (fr)
AU (1)	AU2023416551A1 (fr)
BE (1)	BE1031219B1 (fr)
IL (1)	IL321711A (fr)
WO (1)	WO2024141570A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119306841B (zh) *	2024-12-13	2025-03-07	北京细胞治疗集团有限公司	一种pb转座酶单克隆抗体及其检测试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4628587A3 (fr)	2016-04-15	2026-02-25	Memorial Sloan Kettering Cancer Center	Compositions de lymphocytes t transgéniques et de lymphocytes t à récepteur antigénique chimérique et procédés associés
WO2019046636A1 (fr) *	2017-08-30	2019-03-07	The Broad Institute, Inc.	Édition basée sur crispr de type hdr à double sélection
US20220273715A1 (en) *	2019-07-25	2022-09-01	Precision Biosciences, Inc.	Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
EP4034640A4 (fr) *	2019-09-23	2023-10-25	Regents Of The University Of Minnesota	Cellules immunitaires génétiquement éditées et procédés de traitement

2022
- 2022-12-28 BE BE20226101A patent/BE1031219B1/fr active IP Right Grant
2023
- 2023-12-28 KR KR1020257024824A patent/KR20250127145A/ko active Pending
- 2023-12-28 JP JP2025538430A patent/JP2026501380A/ja active Pending
- 2023-12-28 AU AU2023416551A patent/AU2023416551A1/en active Pending
- 2023-12-28 CN CN202380089444.4A patent/CN120569472A/zh active Pending
- 2023-12-28 WO PCT/EP2023/087873 patent/WO2024141570A1/fr not_active Ceased
- 2023-12-28 IL IL321711A patent/IL321711A/en unknown
- 2023-12-28 EP EP23844100.0A patent/EP4623080A1/fr active Pending

Also Published As

Publication number	Publication date
JP2026501380A (ja)	2026-01-14
EP4623080A1 (fr)	2025-10-01
KR20250127145A (ko)	2025-08-26
AU2023416551A1 (en)	2025-07-17
BE1031219B1 (fr)	2024-07-29
WO2024141570A1 (fr)	2024-07-04
CN120569472A (zh)	2025-08-29
BE1031219A1 (fr)	2024-07-23

Publication	Publication Date	Title
Zhao et al.	2018	Universal CARs, universal T cells, and universal CAR T cells
US20230310502A1 (en)	2023-10-05	Targeted replacement of endogenous t cell receptors
AU2015249655B2 (en)	2021-01-07	Chimeric antigen receptors (CAR) for use in therapy and methods for making the same
IL267543B2 (en)	2024-07-01	Modified nk-92 cells and compositions thereof for use in the treatment of cancer and methods of preparation thereof
IL285286B2 (en)	2023-11-01	Transpase polypeptides and uses thereof
IL295470A (en)	2022-10-01	Bcma car-t cells with enhanced activities
IL269515B2 (en)	2023-05-01	chimeric antigen receptor
CN115960204B (zh)	2023-08-25	Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
US20220211758A1 (en)	2022-07-07	Affinity maturated t cell receptors and use thereof
WO2022187288A2 (fr)	2022-09-09	Systèmes et procédés d'annotation à l'échelle génomique d'éléments régulateurs de gènes liés à la condition physique des cellules
IL321711A (en)	2025-08-01	Composition, immune cells comprising same, and use of said immune cells
Gacerez et al.	2018	Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression
IL291832A (en)	2022-06-01	Cell line for tcr discovery and engineering and methods of use thereof
Getts et al.	2019	Synthetic T cell receptor-based lymphocytes for cancer therapy
Bassan et al.	2019	Optimizing T‐cell receptor avidity with somatic hypermutation
Schubert et al.	2023	A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
CN116376824B (zh)	2023-10-10	Nkt细胞、其衍生细胞及在制备抗肿瘤药物中的应用
IL321709A (en)	2025-08-01	The composition and its use in the treatment of hereditary diseases
CN113355362A (zh)	2021-09-07	化学修饰CRISPR/Cpf1复合物的用途
WO2025124489A1 (fr)	2025-06-19	Tcr spécifique à un antigène mutant kras_g12d, et co-expression de tcr et de cd8 pour rediriger des lymphocytes t cd4
Pesch	2019	Molecular and Cellular Engineering of B Cells for Immunotherapy Applications
WO2024160180A1 (fr)	2024-08-08	Composition et procédé de transplantation allogénique
CN120225666A (zh)	2025-06-27	用于评估基因编辑的t细胞的增殖效力的方法
JP2026504480A (ja)	2026-02-05	Ｋｒａｓ結合タンパク質と内在性ｔｃｒのノックアウトとを有する宿主細胞、およびその使用方法
JP2026501695A (ja)	2026-01-16	Ｋｉｔ細胞表面受容体のエピトープ操作